http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20160048988-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dbc62afae9e5385f7a3f14090e707a06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D249-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4196 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D249-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D401-10 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4196 |
| filingDate | 2014-09-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dffff3c6d5c1d3a40dca3f6d7d4a187e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_15ae08c6b76a730050fc0690cb98186c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9a7395301ef5f2dfacf9e70b922aad69 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9670edb38147f1a971aabd6995263345 |
| publicationDate | 2016-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-20160048988-A |
| titleOfInvention | Triazolone compounds and uses thereof |
| abstract | The invention disclosed herein relates to the compounds of formula (Ia) and (Ib) and their pharmaceutically acceptable salts useful for the treatment of prostate cancer, breast cancer, colon cancer, pancreatic cancer, human chronic lymphocytic leukemia, melanoma and other cancers will be. The invention also includes pharmaceutical compositions comprising a therapeutically effective amount of a compound of formula (Ia) or (Ib), or a pharmaceutically acceptable salt thereof. The invention disclosed herein also relates to methods of treating prostate cancer, breast cancer, ovarian cancer, liver cancer, renal cancer, colon cancer, pancreatic cancer, human chronic lymphocytic leukemia, melanoma and other cancers. The invention disclosed herein further relates to a method of treating prostate cancer, breast cancer, colon cancer, pancreatic cancer, chronic lymphocytic leukemia, melanoma and other cancers, comprising the administration of a therapeutically effective amount of a compound that is a double antagonist of PPAR? And PPAR ?. do. The compounds and pharmaceutical compositions of the invention are also useful for the treatment of viral infections, such as HCV infections and HIV infections. The invention disclosed herein also relates to methods for preventing the onset and / or recurrence of other cancers as well as acute and chronic myelogenous leukemias, including the administration of a therapeutically effective amount of a double antagonist of PPAR [alpha] and PPAR [delta]. |
| priorityDate | 2013-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 531.